Avalo Therapeutics (AVTX)

• Market cap: $244M
• 1 day: -8.35%
• 5 days: -12.43%
• 1 month: -17.84%
• 3 months: -19.94%
• 6 months: 60.61%
• Year to date: -22.62%
• 1 year: 57.16%
• 5 years: -99.87%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23